# Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age

> **NCT02879266** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 28 (estimated)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** TetraVax-DV TV005
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02879266
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2017-09-07
- **Final completion:** —
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879266, "Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02879266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*